Personalized Medicine Market Companies Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts

Global Personalized Medicine Market Size & Forecast 2025-2033

The global personalized medicine market was valued at around US$ 585.53 billion in 2025 and is anticipated to reach nearly US$ 1,009.82 billion by 2033. According to research by Renub Research, the personalized medicine market will see a CAGR of 7.05% from 2025 to 2033. This growth can be associated with advances in genomics and biotechnology, along with increasing demand for treatments tailored to improve therapeutic efficacy and reduce side effects.

Personalized medicine, which is also referred to as precision medicine, is an approach toward diagnosis and treatment that takes into consideration an individual's unique genetic background, lifestyle, and environmental factors. Unlike the more conventional approaches, wherein treatment often involves one-size-fits-all remedies, the application of personalized medicine optimizes therapy by taking into consideration the characteristics of a particular patient and thus, in general, yields better outcomes with fewer side effects.

The popularity of personalized medicine has grown significantly across the world, particularly in view of developments in genomics and biotechnology. Due to the reduced cost of genetic sequencing and the budding sector of data analytics, health practitioners can now make more precise decisions for the particular condition affecting an individual. This shift has gained traction in areas such as oncology, where targeted therapies can vastly improve survival rates by focusing on specific mutations within tumors.

Besides this, increasing health and well-being awareness among people, along with active participation of patients, has created demand for therapies that can connect to them on a personal note. With continuous research and availability of more therapies, the role of personalized medicine will continue to increase globally in the years to come.

Top Personalized Medicine Manufacturers

Abbott Laboratories

Headquarters: United States of America

Founded: 1888

Abbott Laboratories is one of the leading medical device and healthcare companies that discovers, develops, manufactures, and sells diversified products in the world market. The business portfolio of Abbott includes gastroenterology and women's health, cardiovascular and metabolic health, pain management, central nervous system disorders, and many more. It also covers respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies along with point-of-care systems. Its portfolio also comprises rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Its product portfolio encompasses a wide range of vascular and structural heart needs as well as neuromodulation therapies. Abbott undertakes to market its products primarily through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retail buyers, among independent retailers. The company markets its products in North America, Latin America, the Middle East, Europe, the Asia-Pacific, and Africa.

GE Healthcare, Inc.

Founded: 1892

Headquarters: United States of America

GE HealthCare Technologies Inc (GE HealthCare) is a medical technology, pharmaceutical diagnostics, and digital solutions company. The company designs, develops, manufactures, and markets diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing, and cellular technologies; imaging agents used during medical scanning procedures; and healthcare IT solutions. It also offers performance improvement and performance solutions services, computerized data management, and remote diagnostic and repair services of the company-manufactured and other medical equipment. The company primarily operates its business through subsidiaries and affiliates located worldwide.

Aadi Bioscience, Inc.

Founded: 2011

Headquarters: United States

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company headquartered in Los Angeles, California, focused on precision therapies for genetically-defined cancers, especially those driven by aberrations in the mTOR pathway. The company's lead program is an albumin-bound nanoparticle formulation of sirolimus (nab-sirolimus), designed to overcome the limitations of existing mTOR inhibitors by improving drug delivery, targeting, and safety. Aadi is committed to treating ultra-rare cancers, including malignant perivascular epithelioid cell tumors (PEComa), while expanding its pipeline toward additional mTOR-driven diseases. AADI Bioscience The firm uses genomic profiling to match patients with mTOR-pathway alterations, epitomizing a precision-medicine model. It has recently been acquired by Japan-based KAKEN Pharmaceutical Co., Ltd. in March 2025, enhancing its global reach and resources. With a science-first mindset, a leadership team experienced in launching novel therapeutics, and a growing focus on rare and difficult-to-treat cancers, Aadi Bioscience is positioned at the cutting edge of targeted oncology.

Illumina Inc.

Founded: 1998

Headquarters: San Diego, CA

Illumina Inc. is a US-based biotechnology company and one of the leading companies in the development of integrated systems for the analysis of genetic variation and biological functions. Its customers include pharmaceutical companies, genomic research centers, clinical research organizations, and other biotechnology companies. Illumina has taken various strategic initiatives over the years through which it has enhanced its product portfolio while increasing its presence across geographies. It partnered with aploX in December 2023 to locally manufacture sequencing instruments in China, thereby providing better access to advanced sequencing in the region.

QIAGEN

Founding: 1984

Head Office: Netherlands

Qiagen NV (Qiagen) is a global supplier of molecular testing solutions. Qiagen supplies technologies to be used for the extraction and processing of proteins, DNA and RNA from different sample materials including blood and tissues. Qiagen develops assay technology to detect genetic data in tumours and pathogens, and also bioinformatics applications for interpreting advanced genomic data. Its automation tools automate molecular tests procedures in a lab. Qiagen addresses a diverse range of markets, including human healthcare, veterinary testing, forensic science, food safety, pharmaceuticals, and life sciences research. The company's products are sold directly and through independent distributors. Geographically, it has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Product Launches in the Personalized Medicine Market

Eli Lilly and Company

June 2025, Welldoc(R), a leading innovator in AI-powered digital health, today announced its cardiometabolic digital health platform will power the newly launched Lilly Health(TM) Personalized Health & Medicine Platform* (Lilly Health app). The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company's incretin-based therapies for the treatment of cardiometabolic conditions such as obesity, type 2 diabetes and moderate- to-severe obstructive sleep apnea and obesity. Initially, the Lilly Health app will be available for patients prescribed Zepbound(R) (tirzepatide)** or Mounjaro(R) (tirzepatide)**.

Takeda Pharmaceutical Company Ltd

Sept. 2022, Takeda announced the national launch of the CDPATH(TM) program, including an innovative, validated personalized prognostic tool that utilizes blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease management plan.

SWOT Analysis of the Company

Thermo Fisher Scientific Inc.

Strengths include a broad technological portfolio, state-of-the-art analytical tools, and leadership in genomics and molecular diagnostics.

The main strength of Thermo Fisher Scientific Inc. in the personalized medicine market is its comprehensive technological portfolio, advanced analytical tools, and leadership in genomics and molecular diagnostics. The company provides critical infrastructure for personalized healthcare through its advanced genomic sequencing platforms, bioinformatics solutions, and precision diagnostic instruments. With the ability to analyze patient-specific genetic data, its products help researchers and clinicians accelerate the development of targeted therapies. The strong global presence of Thermo Fisher, backed by robust manufacturing and distribution capabilities, ensures scalability and access throughout clinical and research settings. In addition, working with pharmaceutical and biotechnology companies opens up new avenues of innovation in biomarker discovery and companion diagnostics. The company's integrated approach combining data analytics with automation and clinical insight positions it as a key enabler of personalized treatment strategies. By innovation and scientific excellence, Thermo Fisher Scientific empowers the precision medicine ecosystem to drive next-generation improvements in diagnostic precision and personally tailored patient outcomes worldwide.

Novartis AG

Strengths: Strong R&D capabilities, diversified therapeutic portfolio, and strategic investment in precision and genomic-based therapies.

Novartis AG is uniquely positioned in the market for personalized medicine because of its strong R&D capabilities, diversified therapeutic portfolio, and strategic investment in precision and genomic-based therapies. The company has been at the forefront globally of the development of targeted treatments based on molecular and genetic profiling in critical therapeutic areas such as oncology, immunology, and rare diseases. Its strong pipeline includes breakthrough cell and gene technology-based therapies such as CAR-T therapy. This represents the leadership of Novartis in individualized treatment approaches. Digital health platforms and data-driven clinical research at Novartis facilitate the process of biomarker identification and optimization of therapeutic efficacy. With a large network of research collaborations with academic institutions and biotech firms around the world, Novartis accelerates the translation of precision medicines from the laboratory to the clinic. Furthermore, Novartis demonstrates strong regulatory expertise and commitment to patient-centered innovation, enhancing its competitive advantage. As a science-driven leader, Novartis continues to reshape healthcare by delivering tailored, effective, and transformative therapies in the field of personalized medicine.

Recent Development in the Personalized Medicine Market

AbbVie Inc.

August 2025, AbbVie announced it was investing $195 million into its North Chicago, Illinois facility to increase its active pharmaceutical ingredient production domestically in the United States. This investment is part of AbbVie's previously announced commitment to invest over $10 billion of capital in the United States to broadly support innovation and increase critical manufacturing capabilities and capacity. Active pharmaceutical ingredient manufacturing is a complex and multi-step process that involves producing the active components responsible for the therapeutic effects of medications. The new North Chicago API facility will increase AbbVie's chemical synthesis capabilities in the United States, supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines.

Hoffmann-La Roche Ltd.

September 2025 - Roche announced it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage). The transaction is expected to close in the fourth quarter of 2025.

Sustainability Objective

Danaher Corporation

At Danaher Corporation, sustainability means lower environmental impact, responsible innovation, and improved health outcomes worldwide. Through the DBS, Danaher integrates sustainability into continuous improvement in all parts of its operations. Danaher is committed to a low-carbon future through ambitious reductions in greenhouse gas emissions, increased energy efficiency, and renewable energy utilization across global operations. It reduces waste, preserves water, and designs more sustainable products to make sure its scientific instruments, diagnostics, and bioprocess technologies advance a cleaner, safer world. Danaher engages in responsible supply chain management and collaborates with suppliers to implement environmental and labor standards. A core part of social responsibility at Danaher includes investments in the education of science, technology, engineering, and mathematics students, global health programs, and diversity, equity, and inclusion within the workforce. By combining innovation and environmental stewardship, Danaher Corporation has aimed to create measurable impact and long-term value for customers, communities, and the planet.

Exact Sciences Corporation

Exact Sciences Corporation's sustainability goals focus on environmental responsibility, patient-centered innovation, and corporate accountability. As a leader in cancer diagnostics, the company aims to reduce its ecological footprint while advancing early detection technologies. Exact Sciences is committed to minimizing waste across its laboratories and production facilities, optimizing energy use, and improving the recyclability of packaging materials used in test kits such as Cologuard. The company emphasizes sustainable product development by designing diagnostics that use fewer resources without sacrificing a high level of accuracy. Furthermore, Exact Sciences integrates ethical sourcing, responsible manufacturing, and employee health and safety into its ESG strategy. Social sustainability is of equal importance-thru community screening programs and healthcare partnerships, the company supports improved access to lifesaving diagnostics. With science at the forefront and paired with environmental and social responsibility, Exact Sciences Corporation works to create a healthier, more sustainable future for patients and the global community at large.

Market Segmentations

Global Personalized Medicine Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Global Personalized Medicine Market

Abbott Laboratories

Overview

• Company History and Mission
• Business Model and Operations

Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

1. Abbott Laboratories

2. GE Healthcare, Inc.

3. Aadi Bioscience, Inc.

4. Illumina, Inc.

5. QIAGEN

6. Eli Lilly and Company

7. Takeda Pharmaceutical Company Ltd

8. AbbVie Inc.

9. F. Hoffmann-La Roche Ltd.

10. Danaher Corporation

11. Exact Sciences Corporation

12. Thermo Fisher Scientific Inc.

13. Novartis AG

14. AstraZeneca plc

15. GlaxoSmithKline plc

16. Biogen Inc.

17. Siemens Healthineers AG

18. Agilent Technologies, Inc.

19. Myriad Genetics, Inc.

20. Amgen Inc.